Form 4: Director Karen Ling Receives Bausch + Lomb Equity Grant

Director Karen Ling acquired 15,842 restricted share units of Bausch + Lomb Corporation as part of an annual director compensation grant.

Summary

• Director Karen Ling was granted 15,842 restricted share units (RSUs) on May 26, 2026.
• The grant was issued under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
• The transaction price for the units was $15.78 per share.
• Following this transaction, the director's total beneficial ownership increased to 61,518 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard annual incentive grant indicates stable corporate governance practices.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders.

Management Comments

• The grant reflects the annual award of restricted share units to non-employee directors under the 2022 Omnibus Incentive Plan.

Industry Context

StockSavvy.ai notes that annual equity grants to non-employee directors are a standard corporate governance practice in the pharmaceutical and medical device industry to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The use of RSU grants for director compensation is consistent with standard practices for large-cap healthcare companies.
• The vesting schedule tied to the annual meeting is a common industry benchmark for board member retention and performance alignment.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard component of director compensation packages.

Next Steps

• Vesting of the granted RSUs prior to the next annual meeting of shareholders.

Key Dates

Keywords

Bausch + Lomb, BLCO, Director Compensation, Insider Transaction, Equity Grant, Form 4